{"entity":{"id":"g1-therapeutics","kind":"company","name":"G1 Therapeutics","aka":["G1 Therapeutics, Inc.","G1"],"tldr":"G1 Therapeutics developed trilaciclib (Cosela), a CDK4/6 inhibitor given before chemotherapy to protect bone marrow, approved in 2021 for small-cell lung cancer; the company was acquired by Pharmacosmos in 2024.","summary":"G1 Therapeutics, based in Research Triangle Park, North Carolina, developed trilaciclib, an intravenous CDK4/6 inhibitor that briefly halts haematopoietic stem cells before chemotherapy so they are spared its damage. The FDA approved it as Cosela in February 2021 to reduce chemotherapy-induced myelosuppression in extensive-stage small-cell lung cancer; a phase 3 trial in triple-negative breast cancer (PRESERVE 2) did not improve survival. Pharmacosmos, the Danish iron-medicine company, acquired G1 in 2024. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials led by G1 Therapeutics","url":"https://clinicaltrials.gov/search?lead=G1%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/G1_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["sclc","tnbc"],"sections":["supportive-care"],"technologies":["cdk46-inhibitor"],"targets":["cdk4-6"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["neutropenia"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Research Triangle Park, NC","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[]},"route":"/companies/g1-therapeutics/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"}],"target":[{"id":"cdk4-6","kind":"target","name":"CDK4/6","route":"/targets/cdk4-6/"}],"term":[{"id":"neutropenia","kind":"term","name":"Neutropenia","route":"/terms/neutropenia/"}]}}